PositiveID files Firefly DX patent
The hand-held device utilizes polymerase chain reactions (PCR) in order to produce a diagnostic result for a multitude of pathogens and other agents.
"We continue to strengthen our intellectual property position for Firefly Dx as our development and testing of the system progresses," PositiveID Chairman and CEO William Caragol said. "With the recent announcement that we are able to deliver positive test results within 20 minutes using our Firefly PCR chip, we are confident that our technology will not only work, but will represent a paradigm shift to the large PCR market."
Existing diagnostic tools can be cumbersome or impossible to use in some situations, particularly in remote areas or areas without the proper laboratory conditions. This device is portable and requires no outside source of electricity. Testing has shown that it is able to provide accurate results in a quick and efficient manner. The company said that results match lab techniques in accuracy and are able to streamline the diagnostic process.
This device's development process was funded by the U.S. Department of Homeland Security in order to better detect threats from airborne biological agents.